Eversept Partners LP Decreases Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Eversept Partners LP lessened its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 75.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,895 shares of the company's stock after selling 307,663 shares during the period. Eversept Partners LP's holdings in Autolus Therapeutics were worth $232,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Wellington Management Group LLP boosted its position in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after buying an additional 1,125,454 shares during the period. Candriam S.C.A. purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at approximately $7,500,000. JPMorgan Chase & Co. grew its stake in Autolus Therapeutics by 145.3% in the third quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock worth $4,663,000 after purchasing an additional 761,008 shares in the last quarter. BIT Capital GmbH increased its holdings in Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock worth $1,497,000 after purchasing an additional 379,050 shares during the period. Finally, Renaissance Technologies LLC raised its position in Autolus Therapeutics by 146.7% during the 4th quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock valued at $1,455,000 after purchasing an additional 368,071 shares in the last quarter. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Trading Down 5.0 %

AUTL traded down $0.07 during trading on Friday, hitting $1.33. The company's stock had a trading volume of 2,740,804 shares, compared to its average volume of 1,464,326. The firm has a market capitalization of $353.91 million, a price-to-earnings ratio of -1.10 and a beta of 2.06. Autolus Therapeutics plc has a twelve month low of $1.11 and a twelve month high of $5.00. The business's fifty day simple moving average is $1.63 and its 200 day simple moving average is $2.45.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million during the quarter, compared to analysts' expectations of $2.98 million. As a group, equities research analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AUTL has been the subject of several recent research reports. Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Truist Financial lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company cut their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.